Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report - Takeaways - MDSpire

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

  • By

  • Saki Tsuchimochi

  • Hiromichi Nakajima

  • Yukako Hattori

  • Shioto Oda

  • Hiroki Imada

  • Tetsuro Taki

  • Anna Matsuoka

  • Shogo Watanabe

  • Akira Hirota

  • Mai Shimura

  • Misao Fukuda

  • Chikako Funasaka

  • Kenichi Harano

  • Nobuaki Matsubara

  • Yoichi Naito

  • Ako Hosono

  • Genichiro Ishii

  • Toru Mukohara

  • June 2, 2026

  • 0 min

Share

  • 1

    Epithelioid hemangioendothelioma (EHE) is a rare vascular neoplasm with no standard systemic therapy, often misdiagnosed due to nonspecific symptoms.

  • 2

    A 33-year-old woman with advanced pulmonary EHE presented with chronic cough, arthralgia, digital clubbing, and developed cardiac tamponade requiring drainage.

  • 3

    Histopathology confirmed EHE, and imaging revealed hypertrophic pulmonary osteoarthropathy (HPOA) with periosteal abnormalities.

  • 4

    The patient was treated with paclitaxel/carboplatin plus bevacizumab and zoledronic acid, resulting in temporary relief of symptoms and effusions.

  • 5

    This case suggests that anti-VEGF therapy may benefit advanced PEH and highlights the potential role of bisphosphonates in managing PEH-associated HPOA.

Original Source(s)

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

  • by Saki Tsuchimochi, Hiromichi Nakajima, Yukako Hattori, Shioto Oda, Hiroki Imada, Tetsuro Taki, Anna Matsuoka, Shogo Watanabe, Akira Hirota, Mai Shimura, Misao Fukuda, Chikako Funasaka, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Genichiro Ishii, Toru Mukohara

  • June 2, 2026

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • by

  • June 1, 2026

  • 5 min